Figure 4.

Helios⁻ and Helios⁺ Treg protect mice from IBD. CD4⁺RFP⁻CD45RB^hi T cells from 8–12 week old CD45.1 mice were injected r.o. into 8–10 week old B6.SJL RAG^−/− recipients. Helios⁻ or Helios⁺ Treg from congenically marked (CD45.2) reporter mice were co-injected where indicated. (A) Mice were monitored weekly for weight loss. Data shown as mean percent weight change from original weight, representative of four independent experiments with n=5 mice per experiment. (B) Effector cells (CD4⁺TCRβ⁺CD45.1⁺) from the mesenteric lymph node were analyzed at 10–11 wks by intracellular staining for cytokine production. Data shown as mean ± SD, representative of four independent experiments with n=5 mice per experiment. (C) Treg cells (CD4⁺ TCRβ⁺CD45.2⁺) were quantified at 10–11 wks from the mesenteric node (left), were analyzed for RFP (Foxp3) expression (middle) and total Foxp3⁺ Treg calculated (right). Data shown as mean ± SD, representative of four independent experiments with n=5 mice per experiment. (D) Foxp3⁺ Treg in (C) were analyzed for Helios expression. Data shown as the percent of CD4⁺ TCRβ⁺CD45.2⁺ Foxp3⁺ cells that express Helios. Data shown as mean ± SD, representative of four independent experiments with n=5 mice per experiment (left) or a representive histogram.